Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Bristol-Myers Squibb Company (BMY) is a leading biopharmaceutical firm focused on discovering, developing, and delivering innovative medicines for serious diseases. Key products include the oncology drug Opdivo and the immunology treatment Orencia, with significant market presence in the U.S. and Europe. The company's strong pipeline and recent acquisitions enhance its competitive position in the oncology and immunology sectors.
Bristol-Myers generates revenue primarily through the sale of patented pharmaceuticals, leveraging strong pricing power due to the efficacy and uniqueness of its products. The company benefits from a robust R&D pipeline, with a focus on innovative therapies that address unmet medical needs, providing a competitive edge in the market.
FDA approvals for new drugs or indications, particularly in oncology and immunology
Clinical trial results for pipeline drugs, especially those targeting high-prevalence diseases
Changes in pricing regulations or reimbursement policies in key markets like the U.S. and Europe
M&A activity that could enhance the product portfolio or pipeline
Regulatory changes that could impact drug pricing and market access
Technological disruption in drug development processes
Increased competition from generics and biosimilars, particularly for key products like Revlimid
Emergence of new therapies from competitors that could capture market share
High debt levels (Debt/Equity of 2.22) may limit financial flexibility
Potential pension obligations impacting cash flow
moderate - while healthcare spending is generally resilient, economic downturns can impact prescription volumes and pricing pressures.
Rising interest rates can increase the cost of capital for R&D investments and may pressure valuations, particularly for growth-oriented firms like BMY.
minimal - the company has a strong cash flow position, reducing reliance on external financing.
growth - due to the company's strong pipeline and potential for high revenue growth from new drug approvals.
moderate - historical volatility reflects the inherent risks in the pharmaceutical sector.
